AK139 for moderate-to-severe atopic dermatitis
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called AK139 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can help reduce skin symptoms and itching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with atopic dermatitis (eczema) for at least 6 months.
- Your eczema covers at least 10% of your body and is moderate to severe (a doctor will check).
- You have moderate to severe itching (at least 4 on a 0-10 scale) on average over a week.
- You have tried topical treatments (like creams) but they didn't work well enough or caused side effects.
- You agree to use effective birth control from the start of the study until 90 days after the last dose.
- You have not used certain strong eczema treatments (like oral steroids, immune suppressants, or light therapy) in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.
This trial tests a new medication called AK120, given as an injection, to see if it helps teenagers with moderate-to-severe eczema (also called atopic dermatitis) that is not well controlled. It may be a good option for teens who need stronger treatment.
This trial tests a new drug called AK120 for adolescents aged 12 to under 18 with moderate-to-severe atopic dermatitis (eczema). It aims to see if AK120 can improve skin symptoms and quality of life.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.